- Home
- USIO vs CELU Comparison
USIO vs CELU Comparison
Compare USIO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- CELU
- Stock Information
- Founded
- USIO 1998
- CELU 2016
- Country
- USIO United States
- CELU United States
- Employees
- USIO 111
- CELU N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- CELU Health Care
- Exchange
- USIO Nasdaq
- CELU Nasdaq
- Market Cap
- USIO 47.7M
- CELU 42.2M
- IPO Year
- USIO N/A
- CELU N/A
- Fundamental
- Price
- USIO $1.77
- CELU $3.22
- Analyst Decision
- USIO Strong Buy
- CELU
- Analyst Count
- USIO 1
- CELU 0
- Target Price
- USIO $4.00
- CELU N/A
- AVG Volume (30 Days)
- USIO 100.0K
- CELU 585.6K
- Earning Date
- USIO 08-06-2025
- CELU 05-08-2025
- Dividend Yield
- USIO N/A
- CELU N/A
- EPS Growth
- USIO N/A
- CELU N/A
- EPS
- USIO 0.12
- CELU N/A
- Revenue
- USIO $83,970,504.00
- CELU $54,220,000.00
- Revenue This Year
- USIO $16.02
- CELU $23.29
- Revenue Next Year
- USIO $13.24
- CELU N/A
- P/E Ratio
- USIO $14.96
- CELU N/A
- Revenue Growth
- USIO 0.46
- CELU 138.11
- 52 Week Low
- USIO $1.24
- CELU $1.00
- 52 Week High
- USIO $2.92
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- USIO 62.02
- CELU 63.79
- Support Level
- USIO $1.72
- CELU $2.95
- Resistance Level
- USIO $1.83
- CELU $3.44
- Average True Range (ATR)
- USIO 0.11
- CELU 0.38
- MACD
- USIO -0.00
- CELU 0.08
- Stochastic Oscillator
- USIO 56.72
- CELU 56.26
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.